HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)

HYZAAR Versus Ramipril Diabetic Patients

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00480805

Enrollment

312

Registered

2007-05-31

Start date

2001-08-08

Completion date

2002-10-16

Last updated

2024-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Type 2 Diabetes Mellitus

Brief summary

A study to test the safety and efficacy of HYZAAR as compared to Ramipril in patients with type 2 diabetes mellitus (high blood sugar) and hypertension (high blood pressure).

Interventions

DRUGMK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks

DRUGComparator : ramipril /Duration of Treatment : 8 Weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient is at least 18 years old, has been diagnosed with type 2 diabetes mellitus

Exclusion criteria

* Patient has renal disease, malignant hypertension, uncontrolled type 2 diabetes mellitus, history of stroke, TIA (Transient Ischemic Attacks) , or heart disease

Design outcomes

Primary

Measure	Time frame
To determine the antihypertensive effectiveness of HYZAAR as compared to Ramipril as measure by SiSBP at Week 4	—

Secondary

Measure	Time frame
To determine the safety anf tolerability of HYZAAR as compared to Ramipril as seen in overall adverse experiences for the duration of the study	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026